Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clonidine + methylphenidate
- Development stage
- Phase 3
- Lead developer
- Tris Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of clonidine, an alpha-2 adrenergic receptor agonist, and methylphenidate, a central nervous system stimulant. This combination is used primarily for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), particularly when either medication alone doesn't provide complete symptom relief. Clonidine helps control attention and hyperactivity by increasing norepinephrine in the brain, while methylphenidate works by increasing dopamine levels.
02
Targets
ADRA1A (α1A)ADRA2B (α2B)ADRA2C (α2C)DAT (Dopamine plasma membrane transport protein)IR (Imidazoline receptor)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)ADRA2A (α2A)
Beyond the preview
Go deeper on clonidine + methylphenidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clonidine + methylphenidate.